Monitoring of Epstein‐Barr virus load after hematopoietic stem cell transplantation for early intervention in post‐transplant lymphoproliferative disease
- 18 January 2008
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 80 (3) , 441-454
- https://doi.org/10.1002/jmv.21096
Abstract
Epstein‐Barr virus (EBV)‐associated post‐transplant lymphoproliferative disease is a life‐threatening complication following hematopoietic stem cell transplantation. A quantitative polymerase chain reaction to evaluate EBV‐genome copy numbers based on a nested polymerase chain reaction and an end‐point dilution was used. Applying this assay EBV load was prospectively screened weekly in 123 patients after transplantation. The results demonstrate that EBV reactivations with more than 1,000 EBV‐genome copies measured in 105peripheral blood mononuclear cells were observed in 31 patients (25.2%). Three patients developed lymphoproliferative disease with extremely high EBV‐genome copies in peripheral blood mononuclear cells (>100,000 copies/105cells) and plasma. After combined antiviral and immune therapy two of three patients showed a dramatic decrease of EBV load and survived, while the third patient died of lymphoma. A subclinical EBV reactivation was observed in 24 cases (19.5%) with EBV‐genome copies in 105peripheral blood mononuclear cells ranging between 2,500 and mostly 10,000. After reduction of immunosuppression the EBV levels normalized. In four patients, the high copy number of ≥80,000 copies/105peripheral blood mononuclear cells and plasma positivity prompted us to start pre‐emptive therapy with rituximab and cidofovir for prevention of lymphoproliferative disease. After drug administration the high EBV load was reduced remarkably. Ninety‐two patients (74.8%) who had ≤1,000 copies/105peripheral blood mononuclear cells did not develop EBV‐associated lymphoproliferative disease. In conclusion, monitoring of EBV load is a sensitive and useful parameter in the surveillance of EBV reactivation for early intervention in EBV‐associated lymphoproliferative disease as well as for follow‐up of the efficacy of therapy. J. Med. Virol. 80:441–454, 2008.Keywords
This publication has 79 references indexed in Scilit:
- Comparison of Various Blood Compartments and Reporting Units for the Detection and Quantification of Epstein-Barr Virus in Peripheral BloodJournal of Clinical Microbiology, 2007
- Comparison of a LightCycler-based real-time PCR for quantitation of Epstein-Barr viral load in different clinical specimens with semiquantitative PCRJournal of Medical Virology, 2006
- Recent developments in the prevention and treatment of Epstein–Barr virus-associated lymphoproliferative diseasesExpert Opinion on Therapeutic Patents, 2004
- Epstein–Barr virus and gastric carcinomaSeminars in Cancer Biology, 1996
- The role of Epstein—Barr virus in the pathogenesis of Hodgkin's diseaseAnnals of Oncology, 1996
- EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER FOLLOWING AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR NON-HODGKINʼS LYMPHOMATransplantation, 1993
- Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipientsVirchows Archiv B Cell Pathology Including Molecular Pathology, 1991
- T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus InfectionsNew England Journal of Medicine, 1988
- VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMAThe Lancet, 1964
- A sarcoma involving the jaws in african childrenBritish Journal of Surgery, 1958